Replies to post #9570 on OncoSec Medical Inc (ONCSQ)

[lasers]

ASCO Selection of Abstracts

Abstracts of superior quality will be selected by the ASCO Scientific Program Committee for presentation at the 2014 ASCO Annual Meeting and for publication in the 2014 ASCO Annual Meeting Proceedings, a supplement to the Journal of Clinical Oncology. The ASCO Scientific Program Committee strongly encourages the submission of abstracts on translational research as the Committee works to increase the number of meritorious translational abstracts presented at the Meeting.

Abstracts will be judged solely on the data submitted. Statements such as “further data will be presented” are strongly discouraged and will decrease the likelihood that the abstract will be selected for presentation at the Annual Meeting.

The Biostatistics Core of the Scientific Program Committeewill conduct formal statistical review of all abstracts representing phase III trials and of other abstracts as determined by Program Committee tracks. A member of the Biostatistics Core will be a voting member of each Committee track, and his or her recommendations regarding the statistical validity of the abstract and its conclusions will influence the selection decisions. Failure to follow the biostatistical guidelines will have a negative impact on the grading of the abstract by the Scientific Program Committee, decreasing the likelihood of presentation at the Annual Meeting.

Each first author will receive a letter of notification via email from the Committee regarding its decision on the abstract in late March. Each first author of a Late-Breaking Abstract will receive a letter of notification regarding the final decision in mid-April.

http://am.asco.org/selection-abstracts-0